ClinicalTrials.gg
CompletedNCT05501769TACTIVE-EUpdated Sep 26, 2025

ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer

A Phase 1 interventional study of ARV-471 in combination with Everolimus in Breast Cancer, sponsored by Arvinas Estrogen Receptor, Inc.. Completed at 9 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-26.

Sponsored by Arvinas Estrogen Receptor, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 12 studies testing vepdegestrant in Breast Neoplasms — 1 open to participants now, 6 under way, 2 of them phase 3. vepdegestrant · Breast Neoplasms.

Enrollment
8th of 12
32 · median 48
Started
2022
with 1 other
Phase 1
3 of 12
none open now
Registered
4th of 12
by date
Lead sponsor
2 of 12
Arvinas Estrogen Receptor, Inc.

Among the 12 studies testing vepdegestrant in Breast Neoplasms, this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 3 in phase 1, and was the 4th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,320 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

1 of the 12 studies testing vepdegestrant in Breast Neoplasms is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About vepdegestrant

vepdegestrant: first FDA approval 2026 (VEPPANU). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,399 Breast Neoplasms studies recruiting now, 1,570 (65%) set no upper age limit and 592 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing vepdegestrant in Breast Neoplasms, or all of them as a file.
02

Study summary

A phase 1b study to assess the combination of ARV-471 and everolimus in participants with advanced or metastatic ER+/HER2- breast cancer.

Read the detailed description

This is a Phase 1b study to assess the safety and tolerability of ARV-471 in combination with everolimus in participants with estrogen receptor positive/human epidermal growth factor receptor 2 negative (ER+/HER2-) advanced or metastatic breast cancer, who have received a prior CDK4/6 inhibitor and endocrine therapy in the advanced/metastatic setting.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Advanced breast cancer
  • Metastatic breast cancer
  • MBC
  • Endocrine therapy
  • Estrogen receptor
  • ER+
  • human epidermal growth factor receptor 2
  • HER2-
  • ARV-471
  • Everolimus
  • PROTAC
  • Vepdegestrant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed ER+ and -advanced breast cancer (, recurrent, or unresectable)
  • Women must be , or pre-/peri-menopausal women must be on ovarian suppression
  • or non-measurable (evaluable) disease per v1.1
  • Received a minimum of 1 and up to 3 lines of anti-cancer therapy in the advanced/metastatic setting: must have received and progressed on (or were intolerant to) a CDK 4/6 inhibitor, either alone or in combination; must have received at least one endocrine therapy, either alone or in combination; may have received up to one
  • Must be willing to use dexamethasone mouthwash for the prevention of everolimus-induced stomatitis
  • performance status of 0 or 1

Exclusion criteria

Exclusion Criteria:

  • Untreated or brain metastases requiring above physiologic replacement doses
  • Prior treatment with ARV-471
  • Prior treatment targeting mTOR (e.g. everolimus)
  • Prior anticancer or drug treatment within 28 days (fulvestrant) or 14 days (tamoxifen or aromatase inhibitor, or CDK 4/6 inhibitor) before the first dose of study drug
  • Prior anticancer or investigational anticancer drug therapy within 28 days or 5 half-lives (whichever is shorter) before the first dose of study drug, except as mentioned above
  • Any of the following in the previous 12 months: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident, , symptomatic pulmonary embolism, or other episode of thromboembolism
  • Any of the following in the previous 6 months: congenital long syndrome, Torsade de Pointes, sustained ventricular tachyarrhythmia and ventricular fibrillation, left anterior hemiblock, ongoing cardiac arrythmias/dysrhythmias, atrial fibrillation
  • Hypertension that cannot be controlled by medication (>150/90 mmHg despite optimal medical therapy)
  • Active, uncontrolled bacterial, fungal, or viral infection, including virus, virus, known (HIV), or acquired immunodeficiency syndrome (AIDS)-related illness
  • Known history of drug-induced pneumonitis or other significant symptomatic deterioration of lung function
  • within 14 days before the first dose of study drug
  • Major surgery (as defined by the Investigator) within 4 weeks of first dose of study drug
  • Radiation therapy within 4 weeks of first dose of study drug or prior irradiation to more than 25% of the bone marrow
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    ARV-471 and Everolimus

    ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles

    Drug: ARV-471 in combination with Everolimus

Interventions

  • DrugARV-471 in combination with Everolimus

    Drug pages: Vepdegestrant · Everolimus

    ARV-471 oral tablets in combination with everolimus administered daily in 28 day cycles

06

What researchers measure

Primary outcomes

  1. Incidence of dose limiting toxicities of ARV-471 in combination with everolimus

    Dose limiting toxicities in the first 35 days of the study combination treatment characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), timing, seriousness, and relationship to study drug

    Time frame: 35 Days

  2. Recommended Phase 2 Dose (RP2D) for ARV-471 in combination with everolimus

    Time frame: 35 Days

  3. Number of participants with adverse events as a measure of safety and tolerability of ARV-471 in combination with everolimus

    Adverse events as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drug combination

    Time frame: 28 calendar days after participant discontinues study treatment

  4. Incidence of laboratory abnormalities as a measure of safety and tolerability of ARV-471 in combination with everolimus

    Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE v5.0), and timing

    Time frame: 28 calendar days after participant discontinues study treatment

Secondary outcomes

  1. Overall response rate (ORR) in participants

    Time frame: Up to approximately 1 year

  2. Clinical benefit rate (CBR) in participants.

    Clinical benefit response rate based on the summation of CRs, PRs and stable disease of 24 weeks duration or longer.

    Time frame: Up to approximately 1 year

  3. Duration of response (DOR) in participants

    Time frame: Up to approximately 1 year

  4. Maximum plasma concentrations (Cmax) of ARV-471 and everolimus

    Time frame: At predefined intervals throughout the treatment period, up to approximately 4 weeks after last dose of investigational products

  5. Time to maximum plasma concentrations (Tmax) of ARV-471 and everolimus

    Time frame: At predefined intervals throughout the treatment period, up to approximately 4 weeks after last dose of investigational products

  6. Area under the concentration-time curve over 24 hours at steady state (AUC(0-24)) of ARV-471 and everolimus

    Time frame: At predefined intervals throughout the treatment period, up to approximately 4 weeks after last dose of investigational products

07

Study locations

9 sites
  • Clinical Trial Site
    San Diego, California 92037, United States
  • Clinical Trial Site
    Santa Monica, California 90404, United States
  • Clinical Trial Site
    Washington D.C., District of Columbia 20007, United States
  • Clinical Trial Site
    Lake Mary, Florida 32746, United States
  • Clinical Trial Site
    Ann Arbor, Michigan 48109, United States
  • Clinical Trial Site
    Nashville, Tennessee 37203, United States
  • Clinical Trial Site
    Barcelona, 08028, Spain
  • Clinical Trial Site
    Madrid, 28034, Spain
  • Clinical Trial Site
    Valencia, 46018, Spain
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Jul 2024, 21 months.

Of 389 industry-sponsored phase 1 interventional studies under Breast Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 56. This study's 21 months is below that.

Counting every sponsor, half of 761 studies reached it within 44 months; a quarter within 25 and three quarters within 65.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2022
First posted
Aug 15, 2022
StartActual
Sep 8, 2022
Primary completionActual
Jul 3, 2024
CompletionActual
Aug 25, 2025
Last update
Sep 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05501769
Lead sponsor
Arvinas Estrogen Receptor, Inc.
Collaborators
Pfizer
Responsible party
Sponsor
First posted
Aug 15, 2022
Start date
Sep 8, 2022
Primary completion
Jul 3, 2024
Completion
Aug 25, 2025
Last update
Sep 26, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Vepdegestrant · Everolimus

Start the discussion